Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JW0V
|
|||
| Former ID |
DIB015751
|
|||
| Drug Name |
GCS-100
|
|||
| Indication | Chronic kidney disease [ICD-11: GB61; ICD-10: N18, N18.9] | Phase 2 | [1] | |
| Company |
La jolla pharmaceutical
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Galectin (LGALS) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01843790) A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease. U.S. National Institutes of Health. | |||
| REF 2 | GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010 May 13;115(19):3939-48. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.